Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma
暂无分享,去创建一个
Corwin M Zigler | Corwin M. Zigler | F. Dominici | Yun Wang | D. Schrag | N. Arvold | M. Cefalu | Nils D. Arvold
[1] D. Osoba,et al. A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). , 2016 .
[2] Laura W. Christianson,et al. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. , 2015, International journal of radiation oncology, biology, physics.
[3] F. Dominici,et al. Hospitalization burden and survival among older glioblastoma patients. , 2014, Neuro-oncology.
[4] G. Reifenberger,et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. , 2014, The Lancet. Oncology.
[5] G. Reifenberger,et al. MGMT testing—the challenges for biomarker-based glioma treatment , 2014, Nature Reviews Neurology.
[6] N. Mohile,et al. Treatment Patterns, Survival, and Healthcare Costs of Patients with Malignant Gliomas in a Large US Commercially Insured Population. , 2014, American health & drug benefits.
[7] D. Reardon,et al. Treatment options and outcomes for glioblastoma in the elderly patient , 2014, Clinical interventions in aging.
[8] J. King,et al. Time trends in glioblastoma multiforme survival: the role of temozolomide. , 2013, Neuro-oncology.
[9] R. Stupp,et al. Optimal management of elderly patients with glioblastoma. , 2013, Cancer treatment reviews.
[10] B. Stuart,et al. Use and Spending on Antineoplastic Therapy for Medicare Beneficiaries With Cancer , 2013, Medical care.
[11] Michael Weller,et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. , 2012, Neuro-oncology.
[12] Didier Frappaz,et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.
[13] C. Gross,et al. Immortal time bias: a frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy. , 2012, International journal of radiation oncology, biology, physics.
[14] G. Reifenberger,et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.
[15] Dhruv B. Sharma,et al. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. , 2012, JAMA.
[16] J. King,et al. Adult glioblastoma multiforme survival in the temozolomide era: A population‐based analysis of Surveillance, Epidemiology, and End Results registries , 2012, Cancer.
[17] F. Ducray,et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Beroukhim,et al. A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Menten,et al. A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme , 2010 .
[20] P. Keegan,et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. , 2009, The oncologist.
[21] A. Brandes,et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma , 2009, Cancer.
[22] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[23] Katherine S Panageas,et al. Patterns of care in elderly glioblastoma patients , 2008, Annals of neurology.
[24] V. Tombolini,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients , 2008, Journal of Neuro-Oncology.
[25] Luc Taillandier,et al. Radiotherapy for glioblastoma in the elderly. , 2007, The New England journal of medicine.
[26] Ralph B D'Agostino,et al. Estimating treatment effects using observational data. , 2007, JAMA.
[27] S. Preston‐Martin,et al. A population‐based description of glioblastoma multiforme in Los Angeles County, 1974–1999 , 2005, Cancer.
[28] R. Pazdur,et al. Food and Drug Administration Drug Approval Summary: Temozolomide Plus Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme , 2005, Clinical Cancer Research.
[29] R. Pazdur,et al. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[31] E. Bruera,et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] M. Berger,et al. Epidemiology of primary brain tumors: current concepts and review of the literature. , 2002, Neuro-oncology.
[33] L. Stewart,et al. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.
[34] R. D'Agostino. Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .
[35] Donald Rubin,et al. Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.
[36] R. Deyo,et al. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.
[37] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[38] D P Byar,et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.
[39] Jared K Lunceford,et al. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. , 2017, Statistics in medicine.
[40] V. Esposito,et al. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. , 2015, International journal of radiation oncology, biology, physics.
[41] A. Verma. MGMT Gene Silencing and Benefit From Temozolomide in GlioblastomaHegi ME, Diserens A-C, Gorlia T, et al (Univ Hosp Lausanne, Switzerland; Univ Hosp Geneva; Swiss Inst for Experimental Cancer Research, Epalinges, Switzerland; et al) N Engl J Med 352:997–1003, 2005§ , 2006 .
[42] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.